Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,503 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Accepts healthy volunteers

A Program to Increase Physical Activity Among Blacks

NCT00991731
Conditions
Physical Activity
Interventions
Faith-based, Non-faith-based
Behavioral
Lead sponsor
Melicia Whitt-Glover
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
496 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed Phase 2 Interventional Accepts healthy volunteers

Vitamin A Absorption From Cassava in Women

NCT01381276
Conditions
Vitamin A Deficiency
Interventions
Beta-Carotene bio-fortified cassava porridge without oil, Beta-Carotene bio-fortified cassava porridge with oil, White cassava porridge with retinyl palmitate reference dose
Other
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Davis, California
Conditions
Healthy Adult Participants
Interventions
Selegiline TDS 6 mg/24 hours, EMSAM® TDS 6 mg/24 hours
Drug
Lead sponsor
Corium Innovations, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Completed Not applicable Interventional Results available

Rivanna Ultrasound for Neuraxial Block

NCT03214640
Conditions
Analgesia
Interventions
Rivanna Accuro US Device, Palpation, Neuraxial Analgesia, Spinal Block
Device · Other · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of the H.O.O.V.E.S. Healing Intensives Program

NCT06300255
Conditions
Anxiety, PTSD, Depression
Interventions
H.O.O.V.E.S. Healing Intensives
Behavioral
Lead sponsor
VA Salt Lake City Health Care System
Federal
Eligibility
18 Years to 120 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Facial Rosacea
Interventions
Soolantra® Ivermectin cream 1%, Ivermectin cream 1%, Placebo for Ivermectin cream 1%
Drug
Lead sponsor
Zydus Worldwide DMCC
Industry
Eligibility
18 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Brandon, Florida • Fort Lauderdale, Florida • Miami, Florida + 7 more
Conditions
Prostate Cancer, Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)
Interventions
Tasquinimod, Radium 223
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Of Verapamil

NCT00668967
Conditions
Healthy Volunteers
Interventions
verapamil
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Actinic Keratosis
Interventions
Imiquimod Cream, 3.75%, Zyclara®, Vehicle of Test Product
Drug · Other
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Tucson, Arizona • Encino, California • Los Angeles, California + 20 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2484595 in Healthy Subjects

NCT01450098
Conditions
Healthy Volunteers
Interventions
LY2484595 Reference Formulation (RF), LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Completed Not applicable Interventional Accepts healthy volunteers

A Parent-Based Intervention to Reduce Sexual Risk Behavior in Adolescents

NCT00461487
Conditions
Behavior and Behavior Mechanisms
Interventions
Active control on hygiene and nutrition, Families Talking Together
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
11 Years to 14 Years
Enrollment
530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clarithromycin 500 mg Tablets Under Non-Fasting Conditions

NCT00836706
Conditions
Healthy
Interventions
clarithromycin, BIAXIN®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Completed Not applicable Interventional Accepts healthy volunteers

Automated Screening Device to Detect MTMROP

NCT06517836
Conditions
Retinopathy of Prematurity, ROP
Interventions
iROP DL
Device
Lead sponsor
Siloam Vision
Industry
Eligibility
4 Weeks to 2 Years
Enrollment
1,284 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
Panobinostat 15 MG, Focused Ultrasound with neuro-navigator-controlled sonication
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
4 Years to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Completed No phase listed Observational

FLEX FIRST Registry Research Protocol

NCT05616104
Conditions
Arteriovenous Fistula, Arteriovenous Graft, Fistula, Arterial Occlusive Diseases
Interventions
FLEX Vessel Prep System
Device
Lead sponsor
VentureMed Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Miami, Florida • New Brighton, Minnesota • Orangeburg, South Carolina + 1 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions

NCT00833521
Conditions
Healthy
Interventions
Zolpidem 10 mg tablets, AMBIEN® 10 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Healthy
Interventions
Azithromycin, Zithromax®
Other · Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Blood Glucose Monitoring Systems With Blood Samples From Neonates

NCT01756274
Conditions
Diabetes
Interventions
Contour® NEXT BGMS, Contour® PLUS BGMS, Contour® Next EZ BGMS
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
Up to 30 Days
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Speech Sound Disorder
Interventions
Traditional articulation treatment, Visual-acoustic biofeedback
Behavioral
Lead sponsor
New York University
Other
Eligibility
8 Years to 15 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20mg/day, Placebo
Drug · Other
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 11 Years
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
34
States / cities
Little Rock, Arkansas • Imperial, California • Lemon Grove, California + 29 more
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Ultrasound Biomarkers for Assessing Eligibility and Response to Resmetirom Therapy

NCT07860814
Conditions
Metabolic Dysfunction-steatohepatitis (MASH)
Interventions
Not listed
Lead sponsor
Radnet Management, Inc.
Network
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
3
States / cities
Houston, Texas • Pearland, Texas
Conditions
Melanoma
Interventions
MSB0010445 (0.3 milligram per kilogram [mg/kg]), MSB0010445 (1.0 mg/kg), MSB0010445 (1.8 mg/kg), MSB0010445 (2.4 mg/kg), Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rockland, Massachusetts
Conditions
BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include, Vaginal Discharge Color, Odor, and Consistency, Vulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or Severe, Vulvovaginal Inflammation (Objective) Absent, Mild, Moderate, or Severe
Interventions
clindamycin phosphate vaginal cream 2%, placebo
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
15
States / cities
Birmingham, Alabama • La Mesa, California • San Diego, California + 12 more
Conditions
Healthy
Interventions
10 mg dose MR formulations,10 mg dose of tofacitinib IR solution
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut